Identifying Novel Therapeutic Targets and Combination Strategies for Patients with BPDCN

Abstract

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a highly aggressive hematologic malignancy characterized by poor clinical outcomes and no approved or standard therapies. This project aims to investigate mechanisms of response and resistance to the most advanced targeted therapies in BPDCN, assess potential for combination treatment in a clinical trial, and explore novel mechanism-based therapies targeting recurrently mutated genes in BPDCN involved in RNA splicing. We expect our aims to provide clinical data for the next front-line treatment strategy for BPDCN patients and the preclinical basis to intelligently select the next targeted therapy approach for clinical testing in BPDCN.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2023
Accession Number
AD1223922

Entities

People

  • Andrew A Lane
  • Marina Konopleva
  • Omar Abdel-Wahab

Organizations

  • Dana–Farber Cancer Institute
  • The University of Texas MD Anderson Cancer Center

Tags

Fields of Study

  • Biology
  • Medicine

Readers

  • Circadian Sleep-Wake Regulation and Chronobiology
  • Molecular and genetic basis of cancer.
  • Prostate Cancer Biology.